Silence Therapeutics (NASDAQ:SLN) Hits New 12-Month High – Time to Buy?

Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) hit a new 52-week high on Monday. The stock traded as high as $19.60 and last traded at $19.5850, with a volume of 15,992,139 shares traded. The stock had previously closed at $8.68.

Silence Therapeutics News Roundup

Here are the key news stories impacting Silence Therapeutics this week:

• Positive Sentiment: Merck agrees to acquire Silence for approximately $1.3 billion. Merck KGaA will pay $20 in cash for each American depositary share, representing a 130% premium to Silence’s October 16 closing price and an 82% premium to its 30-day volume-weighted average price. The all-cash consideration provides a clear valuation catalyst and largely removes dependence on the company’s clinical-development timeline. Silence Therapeutics jumps 59% on Merck takeover
• Positive Sentiment: The acquisition strengthens Merck’s rare-disease pipeline. Merck is seeking Silence’s innovative small-interfering RNA technology and lead clinical assets, making the transaction strategically significant beyond the takeover premium. Silence Therapeutics Enters into Agreement to be Acquired by Merck
• Neutral Sentiment: The stock is now primarily a merger-arbitrage situation. With shares close to the $20 cash offer, further upside is limited unless another bidder emerges or the terms improve. The remaining discount reflects the time required for approvals and the risk that the transaction does not close. Silence Therapeutics stock analysis
• Neutral Sentiment: Options activity and analyst estimates are secondary catalysts. Call-option volume rose sharply, while a consensus price target implies substantial upside; however, those indicators are less meaningful after a definitive cash offer has been announced. Silence Therapeutics analyst price target
• Negative Sentiment: Shareholder-law-firm investigations could add deal uncertainty. Brodsky & Smith and Halper Sadeh are examining whether Silence’s board obtained a fair price and followed proper procedures. Such reviews do not necessarily prevent completion, but they could delay the transaction or seek improved terms. Halper Sadeh Silence Therapeutics investigation

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on SLN shares. Morgan Stanley boosted their price target on shares of Silence Therapeutics from $25.00 to $32.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Thursday, October 15th. Jefferies Financial Group downgraded shares of Silence Therapeutics from a “buy” rating to a “hold” rating and set a $20.00 target price for the company. in a report on Monday. Cantor Fitzgerald initiated coverage on Silence Therapeutics in a research report on Wednesday, June 24th. They issued an “overweight” rating on the stock. Finally, William Blair cut Silence Therapeutics from an “outperform” rating to a “hold” rating in a research note on Monday. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Silence Therapeutics presently has an average rating of “Hold” and a consensus target price of $42.33.

Silence Therapeutics Trading Up 0.2%

The business has a fifty day moving average of $12.55 and a 200 day moving average of $9.82. The company has a market capitalization of $1.18 billion, a PE ratio of -15.32 and a beta of 1.45.

Silence Therapeutics (NASDAQ:SLN) last released its earnings results on Monday, August 10th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.12). Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 106.94%. Equities analysts forecast that Silence Therapeutics PLC Sponsored ADR will post -0.82 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Squarepoint Ops LLC increased its stake in Silence Therapeutics by 29.6% during the 2nd quarter. Squarepoint Ops LLC now owns 115,918 shares of the company’s stock worth $1,273,000 after buying an additional 26,449 shares during the period. AXQ Capital LP acquired a new stake in Silence Therapeutics during the 2nd quarter worth approximately $138,000. 5AM Venture Management LLC purchased a new position in Silence Therapeutics in the 2nd quarter valued at approximately $5,228,676. GAMMA Investing LLC boosted its position in Silence Therapeutics by 18.1% in the 2nd quarter. GAMMA Investing LLC now owns 11,063 shares of the company’s stock valued at $121,000 after buying an additional 1,698 shares during the period. Finally, Seven Fleet Capital Management LP boosted its position in Silence Therapeutics by 6.2% in the 1st quarter. Seven Fleet Capital Management LP now owns 156,759 shares of the company’s stock valued at $826,000 after buying an additional 9,159 shares during the period. Institutional investors and hedge funds own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on developing medicines that use RNA interference (RNAi) to selectively reduce the production of disease-causing proteins. The company’s approach is designed to act at the genetic level by targeting specific messenger RNA molecules before they are translated into proteins.

Silence’s research is supported by its proprietary mRNAi GOLD platform, which is intended to enable the development and delivery of small interfering RNA (siRNA) medicines.